Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with serious psychiatric and neurological conditions. Sunovion’s track record of discovery, development and commercialization of important therapies has included Brovana® (arformoterol tartrate), Latuda® (lurasidone HCI), Aptiom® (eslicarbazepine acetate) Lonhala® Magnair® (glycopyrrolate), and, most recently, KYNMOBI® (apomorphine HCI) sublingual film.
Headquartered in Marlborough, MA Sunovion is an indirect, wholly owned subsidiary of Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario, is a wholly-owned direct subsidiary of Sunovion Pharmaceuticals Inc. Find more information at www.sunovion.com and connect on Twitter and Facebook @Sunovion.
LATUDA is a registered trademark of Sumitomo Pharma Co., Ltd.
APTIOM is used under license from BIAL.
BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc.
KYNMOBI is a registered trademark of Sunovion Pharmaceuticals Inc.
LONHALA MAGNAIR is a registered trademarks of Sunovion Pharmaceuticals Inc.
© 2022 Sunovion Pharmaceuticals Inc.
To view our community guidelines, see here: bit.ly/3CozDLX
biotechnology, life sciences, central nervous system, respiratory, copd